ARE — Alexandria Real Estate Equities

Life science REIT. AGI Score 8/10. P/TB 0.55x — trading at 55 cents on the dollar of book value. 8% dividend yield. | Analysis date: 2026-03-13

Why are we looking at this?

Alexandria is the dominant life science REIT — owns Class A lab space in the most irreplaceable innovation clusters (Kendall Square/Cambridge, South San Francisco, San Diego). Trading at 0.55x book value with an 8% dividend yield. Book value is $90.71/share vs stock price of $48.41. The AGI thesis: AGI accelerates drug discovery and biotech R&D, driving explosive demand for wet lab space. At 55 cents on the dollar for irreplaceable life science real estate, this could be a genuine deep value opportunity with AGI upside.

$48.41

Stock Price

$8.4B

Market Cap

0.55x

Price / Book

$3.03B

Revenue (FY2025)

$1.41B

Operating Cash Flow

$1.35B

Free Cash Flow

8.1%

Dividend Yield ($4.68/sh)

$90.71

Book Value / Share

1.32

Beta

Stock Price — ARE

1. The Business

Alexandria is the pioneer and dominant owner of life science real estate in the United States. Founded 1994. The company owns Class A/A+ laboratory, research, and office properties in "AAA innovation clusters" — the handful of locations where biotech and pharma R&D happens.

Portfolio (Dec 31, 2025)

35.9 million RSF (rentable square feet) of operating properties
3.5 million RSF under construction
53% of revenue from investment-grade or large-cap tenants
Megacampus model — multi-building research campuses with amenities, collaboration spaces, shared services

Key Markets (Irreplaceable Locations)

Market	Why Irreplaceable
Greater Boston / Cambridge	Kendall Square — adjacent to MIT, Harvard Medical. Cannot build more lab-zoned land in Kendall Sq.
San Francisco Bay Area	Mission Bay, South San Francisco — adjacent to UCSF, Stanford. Zoning is permanent.
San Diego	Torrey Pines — adjacent to Scripps, UCSD, Salk Institute. Finite land.
Seattle	Lake Union — Fred Hutch, UW. Limited expansion space.
Maryland	Near NIH, FDA. Government research adjacency.
Research Triangle, NC	Duke, UNC. Growing market.

2. Financial History

Metric	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$460M	$2.11B	$2.59B	$2.89B	$3.12B	$3.03B
Net Income	$829M	$645M	$671M	$280M	$511M	-$1.22B
Operating Cash Flow	$883M	$1.01B	$1.29B	$1.63B	$1.50B	$1.41B
CapEx	$283M	$470M	$558M	$629M	$470M	$339M
EPS (diluted)	$3.26	$3.82	$3.18	$0.54	$1.80	-$8.44
Dividends/Share	$4.00	$4.24	$4.48	$4.96	$5.19	$4.68

Balance Sheet Trend

Item	FY2020	FY2022	FY2024	FY2025
Total Assets	$22.8B	$35.5B	$37.5B	$34.1B
Stockholders' Equity	$13.4B	$22.7B	$22.4B	$19.1B
Long-Term Debt	$7.56B	$10.2B	$12.2B	$12.4B
Total Debt (yfinance)	—	—	—	$12.76B
Shares Outstanding	131M	165M	173M	173M

What happened in FY2025?

Net loss of -$1.22B on $3.03B revenue. This is the reason the stock crashed.
Likely large impairment charges on properties — life science real estate has been hit hard by biotech funding slowdown.
Equity dropped from $22.4B to $19.1B — $3.3B decline. Part is the loss, part may be property write-downs.
Revenue declined from $3.12B to $3.03B — first revenue decline in the data. Occupancy issues emerging.
Dividend cut from $5.19 to $4.68/share (-10%). The first cut in ARE's history. Very bearish signal.
OCF still strong at $1.41B — the cash flow machine is still working despite the accounting losses.

3. The Deep Value Case

Book Value Analysis

Book Value Per Share	$90.71
Current Stock Price	$48.41
Discount to Book	47% discount
Total Equity	$19.1B
Market Cap	$8.4B
Implied Real Estate Value at Market Price	$21.2B ($8.4B + $12.8B debt)
Total Assets on Books	$34.1B
Discount to Total Assets	38% discount

No goodwill, no intangible assets. The $34.1B in assets is real — it's land, buildings, and labs. The market is pricing these assets at 62 cents on the dollar.

Is the Book Value Reliable?

Why book value may UNDERSTATE true value

Land in Kendall Square, Mission Bay, Torrey Pines was acquired at historical cost — likely worth 2-5x book
Lab improvements and buildouts appreciated over time
Zoning restrictions make new lab supply extremely limited — existing labs command premium rents
53% investment-grade tenants = stable cash flows

Why book value may OVERSTATE true value

Biotech funding slowdown since 2022 — many tenants are cash-strapped startups
Life science overbuilding in 2020-2022 created oversupply in some markets
The -$1.22B loss suggests management is writing down some properties already
3.5M RSF under construction adds supply into a weakening market
$12.8B debt at rising interest rates pressures margins

4. 10x Reverse Engineering (Bull Case to Entry Price)

Bull Case (2036)

Thesis: AGI accelerates drug discovery massively. Biotech R&D spending doubles. Wet lab space becomes the bottleneck (you need physical labs regardless of AI). ARE's irreplaceable locations in Cambridge/SF/SD command premium rents. Occupancy returns to 95%+. Revenue grows to $5B+.

2036 FFO/share (normalized, 6% growth from ~$6)	$10.75
Bull P/FFO (premium life science REIT)	25x
2036 Price Target	$268
Divide by 10x	$26.80

10x Entry Price: ~$27. ARE's 52-week low is $44.10, and the current price is $48.41. A 10x entry would require another ~45% decline. Not impossible if biotech funding continues to deteriorate or if a dividend elimination panics income investors.

Alternative bull case: If book value is reliable ($90.71/share) and the stock re-rates to 1.5x book, that's $136 — a 2.8x from $48. Not 10x, but a very solid return with 8% dividend along the way.

5. AGI Impact Assessment

AGI Score: 8/10 — Physical Bottleneck

Demand Boost: 8/10 — AGI dramatically accelerates drug discovery, driving demand for wet lab space
Strategic Assets: 9/10 — Irreplaceable locations adjacent to MIT, Stanford, UCSD. Cannot create new lab-zoned land in these clusters.
Margin Expansion: 4/10 — Limited margin expansion potential (REIT structure)
Disruption Risk: 2/10 — Even if AGI enables computational biology, physical wet lab validation remains essential
Innovation Risk: 3/10 — Fully computational biology is 10+ years away, if ever

The AGI thesis for ARE is compelling: Drug discovery becomes 10-100x faster with AGI, but you still need physical labs to validate, test, and manufacture. ARE owns the physical space where this happens.

6. Risks

Biotech funding winter: VC funding for biotech has declined since 2021. If it doesn't recover, lab demand stays weak.
FY2025 impairments: -$1.22B net loss = large write-downs. More could come.
Dividend sustainability: Already cut from $5.19 to $4.68. At $48 stock price, 8% yield looks distressed. Further cuts possible if OCF declines.
Debt load: $12.8B debt with rising rates. Interest expense grew from $94M (2022) to $227M (2025).
Overbuilding: 3.5M RSF under construction adds supply. If demand doesn't absorb it, occupancy falls further.
Concentrated markets: Boston/SF account for majority of revenue. Regional overexposure.

7. Verdict

WATCHLIST — Most interesting on this list. Deep value + AGI tailwind.

ARE is the most compelling company on this list for our framework. It has real, tangible, irreplaceable assets trading at a massive discount to book value. The AGI thesis (drug discovery acceleration = lab demand surge) is genuinely differentiated from the "data center power" thesis that applies to utilities.

Current price ($48.41) provides:

47% discount to book value (irreplaceable life science real estate)
8% dividend yield (even after the cut)
$1.41B OCF on $8.4B market cap = 16.8% OCF yield
Potential 2.8x to book value ($90.71), or 5.6x to 1.5x book ($136)

10x Entry: ~$27. Would need another major selloff. Monitor quarterly for further impairments or dividend cuts.

Floor estimate: $30-35 (0.33-0.38x book). Even if you haircut book value by 50%, equity is worth ~$55/share. At $30-35, you're paying 35-40 cents on the dollar for already-discounted assets. Very little chance of losing money at that level.

Action: Add to deep watchlist. Begin monitoring biotech funding data and ARE occupancy rates quarterly.

Data sources: SEC EDGAR XBRL (CIK 1035443), yfinance, 10-K filing. Analysis date: 2026-03-13.